Similar articles

• Adapalene: a review of its use in the treatment of acne vulgaris.

  Waugh J, Noble S, Scott LJ. Waugh J, et al. Drugs. 2004;64(13):1465-78. doi: 10.2165/00003495-200464130-00005. Drugs. 2004. PMID: 15212561 Review.
• Spotlight on adapalene in acne vulgaris.

  Waugh J, Noble S, Scott LJ. Waugh J, et al. Am J Clin Dermatol. 2004;5(5):369-71. doi: 10.2165/00128071-200405050-00014. Am J Clin Dermatol. 2004. PMID: 15554742 Review.
• [Pharmacological and clinical profiles of adapalene (Differin) gel 0.1%].

  Miyai E, Sugino K. Miyai E, et al. Nihon Yakurigaku Zasshi. 2009 Jul;134(1):37-45. doi: 10.1254/fpj.134.37. Nihon Yakurigaku Zasshi. 2009. PMID: 19602785 Clinical Trial. Japanese. No abstract available.
• The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle.

  Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M; Adapalene Study Group. Pariser DM, et al. Cutis. 2005 Aug;76(2):145-51. Cutis. 2005. PMID: 16209161 Clinical Trial.
• Efficacy and tolerability of adapalene 0.3% gel compared to tazarotene 0.1% gel in the treatment of acne vulgaris.

  Thiboutot D, Arsonnaud S, Soto P. Thiboutot D, et al. J Drugs Dermatol. 2008 Jun;7(6 Suppl):s3-10. J Drugs Dermatol. 2008. PMID: 18575220 Clinical Trial.